Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
Agios Pharmaceuticals has received a 'sell' rating following setbacks with its drug tebapivat and increased competition in the PK activator drug class. The company faces significant risks and challenges, including cash runway concerns. Investors are advised to consider these factors before making decisions regarding AGIO stock.
- ▪Agios Pharmaceuticals is facing a setback with its drug tebapivat.
- ▪The company is experiencing tougher competition in the PK activator drug class.
- ▪Analysts have issued a 'sell' rating on Agios stock due to these challenges.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4910150-agios-sell-on-tebapivat-setback-lr-mds-and-competitive-pk-activator-drug-class"},"author":{"@type":"Person","name":"Terry Chrisomalis","url":"https://seekingalpha.com/author/terry-chrisomalis"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
